NCT03150602Unknown4 期
A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Objective Response Rate
研究概览
简要总结
This study is to evaluate the objective response rate to pralatrexate in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC)
详细描述
Peripheral T-cell lymphomas (PTCL) are a group of aggressive and diverse lymphoproliferative disorders. It is characterized by the presence of malignant mature T-cells or NK cells. There is as yet no consensus regarding standard frontline or relapsed/refractory therapy for PTCL.
A previous phase II study conducted in US showed durable responses of pralatrexate treatment in relapsed or refractory PTCL, irrespective of age, histological subtypes, amount of prior therapy, prior methotrexate, and prior autologous stem-cell transplant. This single-arm, multi-center study aims to evaluate the efficacy and safety of pralatrexate monotherapy in prior treatment failure PTCL patients who may undergo HSCT in case of CR or PR, or continue pralatrexate in case of CR, PR or SD.
Primary objective:
- To evaluate the objective response rate to pralatrexate in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC)
Secondary objectives:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 20 years of age, inclusive
- •Patients with histologically/cytologically confirmed PTCL using either: NCCN diagnosis criteria, the Revised European American Lymphoma (REAL), and World Health Organization (WHO) disease classification (PTCL histology/cytology subtypes diagnosed by site investigators, PTCL histology/cytology subtypes rechecked by study central pathology lab):
- •At least 5 patients with Peripheral T-cell lymphoma, NOS
- •At least 5 patients with Angioimmunoblastic T-cell lymphoma
- •At least 5 patients with Extranodal NK/T-cell lymphoma, nasal type
- •Enteropathy-type T-cell lymphoma
- •Hepatosplenic T-cell lymphoma
- •Subcutaneous panniculitis-like T-cell lymphoma
- •Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+)
- •Patients with documented progressive disease (PD) failed after prior treatment
- •Patients may not have received an experimental drug as their only prior therapy
- •Patient has had at least 1 biopsy from initial diagnosis of PTCL or in the relapsed setting to confirm PTCL subtypes
- •Patient has recovered from the toxic effects of prior therapy
- •Eastern Cooperative Oncology Group (ECOG) Performance Status ≤
- •Adequate hematological, hepatic, and renal function as defined by: absolute neutrophil count (ANC) ≥ 1000/µL, platelet count ≥ 100,000/µL (and ≥ 50,000/µL for any following dose), total bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 X upper limit of normal (ULN) (AST/ALT < 5 X ULN if documented hepatic involvement with lymphoma), creatinine ≤ 1.5 mg/dL or a calculated creatinine clearance ≥ 50 mL/min.
- •Women of childbearing potential must agree to practice medically acceptable contraceptive regimen from 30 days prior to study treatment initiation until at least 30 days after the last administration of pralatrexate and must have had a negative serum pregnancy test within 14 days prior to the first day of study treatment. Patients who are postmenopausal for at least 1 year (> 12 months since last menses) or were surgically sterilized do not require this test.
- •Men who are not surgically sterile must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 90 days after the last administration of pralatrexate.
- •Patient has provided written informed consent (IC)
排除标准
- •Patient has following subtypes (histologically/cytologically confirmed) of PTCL
- •Anaplastic large cell lymphoma, ALK +/-
- •Patient has: Precursor T/NK neoplasms, with the exception of blastic NK lymphoma
- •T-cell prolymphocytic leukemia (T-PLL)
- •T-cell large granular lymphocytic leukemia
- •Mycosis fungoides and transformed mycosis fungoides
- •Sézary syndrome
- •Primary cutaneous CD30+ disorders: Anaplastic large cell lymphoma and lymphomatoid papulosis
- •Patient has: Extranodal NK/T-cell lymphoma, nasal type with local recurrence
- •Active concurrent malignancy (except for non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 5 years.
- •Congestive heart failure Class III/IV according to the New York Heart Association's Heart Failure guidelines.
- •Patients with human immunodeficiency virus (HIV)-positive diagnosis and are receiving combination anti-retroviral therapy.
- •Current or the history of brain metastases or central nervous system (CNS) diseases
- •Have undergone allogeneic stem cell transplant
- •Relapsed less than 75 days from time of autologous stem cell transplant
- •Patients with uncontrolled hypertension, active uncontrolled infection, underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the patient to receive protocol treatment
- •Had major surgery within 2 weeks of study entry
- •Receipt of any conventional chemotherapy or radiation therapy (RT) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the course of the study
- •Receipt of corticosteroids within 7 days of study treatment, unless patient has been taking a stable dose of no more than 10 mg/day of prednisone for at least 1 month
- •Use of any investigational drug, biologic modifier, or device within 4 weeks prior to study treatment or planned use during the course of the study
- •Previous exposure to pralatrexate
- •Other conditions that investigators consider not suitable for study enrollment
研究组 & 干预措施
Pralatrexate treatment
Experimental
Pralatrexate will initially be administered at a dose of 30 mg/m2/week on days 1, 8, 15, 22, 29 and 36 for 6 weeks in a 7-week cycle (cycle: 6 weeks + 1 week rest). The scheduled date can be done within a window time of plus or minus 1 day
干预措施: Pralatrexate (Drug)
结局指标
主要结局
Objective Response Rate
时间窗: Up to 35 weeks
Objective response rate (ORR) to pralatrexate treatment in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC)
次要结局
- Hematopoietic stem cell transplant (HSCT)(Up to 5 years)
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability](Up to 40 weeks)
- 1-year OS rate after HSCT(Up to 1 year)
- Overall survival(Up to 5 years)
- Progression-free survival(Up to 5 years)
- Partial response rate(Up to 5 years)
- Duration of CR and PR(Up to 5 years)
- 1-year PFS rate after HSCT(Up to 1 year)
- 2-year OS rate after HSCT(Up to 2 years)
- 2-year relapse rate after HSCT(Up to 2 years)
- Completion response rate(Up to 5 years)
- Treatment duration(Up to 35 weeks)
- 1-year relapse rate after HSCT(Up to 1 year)
- 2-year PFS rate after HSCT(Up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Pralatrexate for Relapsed or Refractory Peripheral T-cell LymphomaRelapsed or Refractory Peripheral T-cell LymphomaNCT03356678Samsung Medical Center33
已完成
1 期
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative MalignanciesRelapsed or Refractory Lymphoproliferative MalignanciesHodgkin's LymphomaPeripheral T-cell LymphomaWaldenstrom's MacroglobulinemiaB-cell LymphomaNCT00481871Acrotech Biopharma Inc.119
招募中
2 期
POLA-R-CHP in the First-line Treatment of Transformed DLBCLTransformed LymphomaNCT06743945Fudan University20
已完成
2 期
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction CancerAdenocarcinoma of the Gastroesophageal JunctionEsophageal Undifferentiated CarcinomaGastric AdenocarcinomaGastric Squamous Cell CarcinomaRecurrent Esophageal AdenocarcinomaRecurrent Esophageal Squamous Cell CarcinomaRecurrent Gastric CarcinomaStage IIIB Esophageal AdenocarcinomaStage IIIB Esophageal Squamous Cell CarcinomaStage IIIB Gastric CancerStage IIIC Esophageal AdenocarcinomaStage IIIC Esophageal Squamous Cell CarcinomaStage IIIC Gastric CancerStage IV Esophageal AdenocarcinomaStage IV Esophageal Squamous Cell CarcinomaStage IV Gastric CancerUndifferentiated Gastric CarcinomaNCT01178944Roswell Park Cancer Institute35
已完成
2 期
Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer PatientsBreast NeoplasmsNCT00485979Sanofi330